Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma

18 Sept 2017

Abstract excerpt

Abstract Melanoma resistant to MAPK inhibitors (MAPKi) displays loss of fitness upon experimental MAPKi withdrawal and, clinically, may be resensitized to MAPKi therapy after a drug holiday. Here, we uncovered and therapeutically exploited the mechanisms of MAPKi addiction in MAPKi-resistant BRAFMUT or NRASMUT melanoma. MAPKi-addiction phenotypes evident upon drug withdrawal spanned transient cell-cycle slowdown...

Topics

Join the communities discussing this publication.

Cutaneous Melanoma Detection and Management
Immunotherapy and Immune Responses
Melanoma and MAPK Pathways

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28923912
DOI: 10.1158/2159-8290.cd-17-0682

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant MelanomaPMID 28923912Read ↗

Multiple cancer types rapidly escape from multiple MAPK inhibitors to generate mutagenesis-prone subpopulationsSemantic proximity Read ↗

Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.Semantic proximity Read ↗

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.Semantic proximity Read ↗

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITFSemantic proximity Read ↗

Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cellsSemantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.Semantic proximity Read ↗

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.Semantic proximity Read ↗

Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis.Semantic proximity Read ↗

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.